Mary J. Savage

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell et al. · The Lancet Oncology · 2017 · 1.3K citations

Medicine, Oncology, Pharmacology +12

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

Karina Kulangara, Nancy R. Zhang, Ellie Corigliano et al. · Archives of Pathology & Laboratory Medicine · 2018 · 536 citations · Full text

Medicine, Immunology, Oncology +17

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

Jacqueline Vuky, Arjun Vasant Balar, Daniel Castellano et al. · Journal of Clinical Oncology · 2020 · 292 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Activation of c-Jun N-Terminal Kinase and p38 in an Alzheimer's Disease Model Is Associated with Amyloid Deposition

Mary J. Savage, Yin‐Guo Lin, John R. Ciallella et al. · Journal of Neuroscience · 2002 · 290 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Modulation of Secreted β-Amyloid Precursor Protein and Amyloid β-Peptide in Brain by Cholesterol

David Howland, Stephen P. Trusko, Mary J. Savage et al. · Journal of Biological Chemistry · 1998 · 256 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17